Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open indications, some high premiums since 8/17/17

September 5, 2017 7:21am

… I wouldn’t chase this upside

Be ready for the headwinds onward, Cellectis SA (CLLS) feels the force, the pre-market indication is a NEGATIVE -$9.02 or 28%

…. Markets just entered the month of September, which is historically and allegedly the worst month of the year for share pricing performance

Preview RMi's morning call. You’d be reading this if you were a SUBSCRIBER!

Pre-open indications: 0 BUY and 5 SELLs

Out and about: CLLS received notice from the U.S. FDA that a clinical hold was placed on both UCART123 ongoing P1 studies, respectively in acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Critical pre-market indications ahead of “our” universe’s open!

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.